Clinical Trials Logo

Macular Degeneration clinical trials

View clinical trials related to Macular Degeneration.

Filter by:

NCT ID: NCT00457678 Withdrawn - Clinical trials for Age Related Macular Degeneration

Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to demonstrate that Visudyne-Lucentis-dexamethasone (V-L-D) triple therapy will give similar efficacy and safety results as Lucentis monotherapy.

NCT ID: NCT00447031 Withdrawn - Clinical trials for Macular Degeneration

Combination Therapy for Neovascular Age Related Macular Degeneration

Start date: March 2007
Phase: N/A
Study type: Interventional

Exudative age related macular degeneration (ARMD) is most common cause of blindness in old population. It is clear that no single therapy addresses the multifactorial pathogenesis of the disease. Recently, studies of intravitreal anti-VEGF therapies such as pegaptanib and bevacizumab have shown the beneficial effect in visual acuity in the treatment of neovascular ARMD. However, the problem with these intravitreal injections is that therapy must be frequently administered for a prolonged but unknown period of time to maintain the benefit. Prolonged, frequent injections may be associated with additional safety risk,lack of convenience and high treatment cost. Intravitreal steroid injection with anti-inflammatory properties limits any further VEGF upregulation initiated by the inflammation which has been known as one of the pathogenesis and causes of recurrence after the treatment of the neovascular ARMD. The researchers hypothesize that the combined treatment of intravitreal bevacizumab and triamcinolone acetonide may decrease the recurrence rate after the treatment and obviate the frequent intravitreal injections in the treatment of neovascular ARMD. In this study, the researchers will compare the recurrence rate of combined treatment of intravitreal bevacizumab and triamcinolone acetonide versus intravitreal bevacizumab alone in the treatment of neovascular ARMD.

NCT ID: NCT00403156 Withdrawn - Clinical trials for Choroidal Neovascularization

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Start date: November 2006
Phase: Phase 1
Study type: Interventional

The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.

NCT ID: NCT00390026 Withdrawn - Clinical trials for Age-related Macular Degeneration

The Avastin vs Visudyne for Neovascular AMD Study

Start date: November 2006
Phase: Phase 3
Study type: Interventional

The object of the study is to compare the treatment effect of bevacizumab (Avastin), an antibody targeting vascular endothelial growth factor, with verteporfin photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration, the leading cause of vision severe loss in the Western world.